ET1402L1-CART

N/A

Report date: 2024/11/21 20:00:04

Base Information

Drug NameET1402L1-CART
Drug Alias NameAFP-CARET-140202AFP/ET-1402ET1402ET-1402
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAlpha-fetoprotein modulatorsT lymphocyte replacementsImmunologic cytotoxicity
TargetsAlpha-fetoprotein
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesEureka Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEureka Therapeutics IncAeon Therapeutics (Beijing) Co Ltd
Active IndicationsN/A
Inactive IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A